... treating patients: the anti-cancer drug bevacizumab (Avastin) and Copper-64, a radioactive copper ... tumour detection imaging probes. 64Cu-bevacizumab is highly sensitive in pancreatic, breast and lung ...
... Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin ... care is to give patients with GBM the drug bevacizumab (Avastin) intravenously (IV) -- delivering the drug ...
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung ...
... a Gynecologic Oncology Group Phase II clinical trial at M. D. Anderson to test the efficacy of bevacizumab (Avastin), a drug that blocks angiogenesis through antibodies against VEGF ...
... risk of severe or fatal bleeding for certain targeted biological therapies including Bevacizumab (Avastin) and other drugs in development. Other approved therapies such as Pemetrexed (Alimta) are ...
... new agents for the disease. The investigators focused on the use of the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux) because of these drugs' clinical importance, significant ...
... risk of severe or fatal bleeding for certain targeted biological therapies including Bevacizumab (Avastin) and other drugs in development. Other approved therapies such as Pemetrexed (Alimta) are ...
... determine whether adding erlotinib (Tarceva®), a targeted agent, to maintenance therapy with bevacizumab (Avastin®), an agent commonly used as a component of treatment for advanced NSCLC would delay ...
... angiogenesis was involved in these tumors, members of the research team offered treatment with bevacizumab (Avastin), which is FDA-approved for treatment of several forms of cancer, to NF2 patients ...
This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on use of bevacizumab (Avastin), to benefit diabetic patients with macular edema as well as people who develop ...
... at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). ...
